LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) begins its investigation on behalf of G1 Therapeutics, Inc. (NASDAQ: GTHX) investors concerning the Company and its directors’ and officers’ possible violations of state laws.
If you purchased G1 Therapeutics stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com or you may contact Bryan Faubus, of GPM, 230 Park Avenue, Suite 530, New York, NY 10169 at bfaubus@glancylaw.com or at 212-682-5340. If you inquire by email please include your mailing address, telephone number, and the number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.